NeuroSense Therapeutics Ltd.
NRSN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875091
No open-market purchases or sales by NeuroSense Therapeutics Ltd. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $285.7K in total; no superinvestor holds it.
Other share classesNRSNW
Q2 2022 vs. Q1 2022
How the institutions holding NeuroSense Therapeutics Ltd. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 9 | 7 | −2 |
| Shares | 169.0K | 217.3K | +48.3K (+28.6%) |
| Value | $694.0K | $733.0K | +$39.0K (+5.6%) |
New holders (3)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| JustInvest LLC | 39,634 | $134.0K | 0.01% |
| Millennium Management LLC | 20,259 | $68.0K | 0.00% |
| Clear Street LLC | 7,157 | $24.0K | 0.00% |
Sold out (5)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Ikarian Capital, LLC | 100,000 | $397.0K |
| Bank of Montreal | 10,000 | $65.0K |
| Boothbay Fund Management, LLC | 12,170 | $48.0K |
| FNY Investment Advisers, LLC | 1,000 | $3.00K |
| Royal Bank of Canada | 125 | $0 |